Colin A. Flaveny

3.7k citations

34 papers · 2.8k indexed · 2 hit papers · h-index 22

Biological Psychiatry top 0.5%
Behavioral Neuroscience top 5%
Hematology top 2%
Health, Toxicology and Mutagenesis top 2%
- Toxic Organic Pollutants Impact 8
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism 5
- Carcinogens and Genotoxicity Assessment 3
- Cancer, Lipids, and Metabolism 3
Molecular Biology
- Muscle Physiology and Disorders 4
Pharmacology
- Pharmacogenetics and Drug Metabolism 3
Surgery
- Cholesterol and Lipid Metabolism 3
Epidemiology
- Liver Disease Diagnosis and Treatment 3

Co-authors: Gary H. Perdew Iain A. Murray Brett C. DiNatale Jennifer C. Schroeder Elizabeth M. Laurenzana Curtis J. Omiecinski Albert E. Parker Russell D. Romeo
Cited by: Biological Psychiatry Behavioral Neuroscience Hematology
Journals: Science (1 paper)PLoS ONE (3 papers)Biochemistry (1 paper)
Partner nations: United States India Switzerland

In The Last Decade

Colin A. Flaveny

33 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Colin A. Flaveny

Since Specialization

Citations

This map shows the geographic impact of Colin A. Flaveny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin A. Flaveny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin A. Flaveny more than expected).

Fields of papers citing papers by Colin A. Flaveny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin A. Flaveny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin A. Flaveny. The network helps show where Colin A. Flaveny may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Colin A. Flaveny, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Colin A. Flaveny Line = papers co-authored together Colin A. Flaveny links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	STAT1 Drives the Interferon-Like Response and Aging Hallmarks in Progeria PubMed ·Susana Gonzalo,Rafael Cançado de Faria,Elena V. Shashkova,Colin A. Flaveny,Ángel Baldán,Kyle S. McCommis	2023	3
2	A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis PLoS ONE ·Monideepa Sengupta,Suomia Abuirqeba,Amina Kamerić,Aurore Cecile-Valfort,Arindam Chatterjee,Kristine Griffett,Thomas P. Burris,Colin A. Flaveny	2021	9
3	Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice PLoS ONE ·Ryan D. Welch,Cyrielle Billon,Amina Kamerić,Thomas P. Burris,Colin A. Flaveny	2020	5
4	LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer Scientific Reports ·Katherine J. Carpenter,Aurore-Cécile Valfort,Nickolas Steinauer,Arindam Chatterjee,Suomia Abuirqeba,Shabnam Majidi,Monideepa Sengupta,Richard J. Di Paolo,Laurie P. Shornick,Jinsong Zhang,Colin A. Flaveny	2019	53
5	Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract Cell Communication and Signaling ·Subhayan Sur,Hiroshi Nakanishi,Colin A. Flaveny,Joseph E. Ippolito,Jane McHowat,David A. Ford,Ratna B. Ray	2019	56
6	Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome Molecular Metabolism ·Ryan D. Welch,Chun Guo,Monideepa Sengupta,Katherine J. Carpenter,Natalie Stephens,Stacy A. Arnett,Marvin J. Meyers,Lauren M. Sparks,Steven R. Smith,Jinsong Zhang,Thomas P. Burris,Colin A. Flaveny	2017	22
7	REV-ERB and ROR: therapeutic targets for treating myopathies Physical Biology ·Ryan D. Welch,Colin A. Flaveny	2017	7
8	Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle Scientific Reports ·Ryan D. Welch,Cyrielle Billon,Aurore-Cécile Valfort,Thomas P. Burris,Colin A. Flaveny	2017	31
9	Fluorophore-NanoLuc BRET Reporters Enable Sensitive In Vivo Optical Imaging and Flow Cytometry for Monitoring Tumorigenesis Cancer Research ·Franz X. Schaub,Md. Shamim Reza,Colin A. Flaveny,Weimin Li,Adele M. Musicant,Sany Hoxha,Min Guo,John L. Cleveland,Antonio L. Amelio	2015	92
10	Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis Cancer Cell ·Colin A. Flaveny,Kristine Griffett,Bahaa Elgendy,Melissa Kazantzis,Monideepa Sengupta,Antonio L. Amelio,Arindam Chatterjee,John K. Walker,Laura A. Solt,Theodore M. Kamenecka,Thomas P. Burris	2015	160
11	The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis Molecular Metabolism ·Kristine Griffett,Ryan D. Welch,Colin A. Flaveny,Grant R. Kolar,Brent A. Neuschwander‐Tetri,Thomas P. Burris	2015	66
12	Pyrvinium Attenuates Hedgehog Signaling Downstream of Smoothened Cancer Research ·Bin Li,Dennis Liang Fei,Colin A. Flaveny,Nadia Dahmane,Valérie Baubet,Zhiqiang Wang,Feng Bai,Xin‐Hai Pei,Jezabel Rodríguez‐Blanco,Brian Hang,Darren Orton,Lu Han,Baolin Wang,Anthony J. Capobianco,Ethan Lee,David J. Robbins	2014	65
13	Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis PLoS ONE ·Bin Li,Colin A. Flaveny,Camilla Giambelli,Dennis Liang Fei,Lu Han,Brian Hang,Feng Bai,Xin‐Hai Pei,Vânia Nosé,Oname Burlingame,Anthony J. Capobianco,Darren Orton,Ethan Lee,David J. Robbins	2014	53
14	Hedgehog Signaling Regulates Bladder Cancer Growth and Tumorigenicity Cancer Research ·Dennis Liang Fei,Avencia Sánchez-Mejías,Zhiqiang Wang,Colin A. Flaveny,Jun Long,Samer Singh,Jezabel Rodríguez‐Blanco,Robert Tokhunts,Camilla Giambelli,Karoline J. Briegel,Wolfgang A. Schulz,A. Jay Gandolfi,Margaret R. Karagas,Teresa A. Zimmers,Mercè Jordà,P.A. Bejarano,Anthony J. Capobianco,David J. Robbins	2012	41
15	Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cellsbreakdown → Science ·Anthony E. Boitano,Jian Wang,Russell D. Romeo,Laure C. Bouchez,Albert E. Parker,Sue Sutton,John R. Walker,Colin A. Flaveny,Gary H. Perdew,Michael S. Denison,Peter G. Schultz,Michael P. Cooke	2010	772
16	Suppression of Cytokine-Mediated Complement Factor Gene Expression through Selective Activation of the Ah Receptor with 3′,4′-Dimethoxy-α-naphthoflavone Molecular Pharmacology ·Iain A. Murray,Colin A. Flaveny,Christopher Chiaro,Arun Sharma,Rachel Tanos,Jennifer C. Schroeder,Shantu Amin,William H. Bisson,Siva K. Kolluri,Gary H. Perdew	2010	42
17	The Uremic Toxin 3-Indoxyl Sulfate Is a Potent Endogenous Agonist for the Human Aryl Hydrocarbon Receptor Biochemistry ·Jennifer C. Schroeder,Brett C. DiNatale,Iain A. Murray,Colin A. Flaveny,Qiang Liu,Elizabeth M. Laurenzana,Jyh Ming Lin,Stephen C. Strom,Curtis J. Omiecinski,Shantu Amin,Gary H. Perdew	2009	263
18	Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity Molecular Pharmacology ·Iain A. Murray,José L. Quiles,Colin A. Flaveny,Brett C. DiNatale,Chris Chiaro,Krishne Gowda,Shantu Amin,Gary H. Perdew	2009	80
19	The Aryl-hydrocarbon receptor does not require the p23 co-chaperone for ligand binding and target gene expression in vivo Toxicology Letters ·Colin A. Flaveny,Gary H. Perdew,Charles A. Miller	2009	12
20	Ah receptor represses acute-phase response gene expression without binding to its cognate response element Laboratory Investigation ·Rushang D. Patel,Iain A. Murray,Colin A. Flaveny,Ann Kusnadi,Gary H. Perdew	2009	81

About Colin A. Flaveny

Colin A. Flaveny is a scholar working on Health, Toxicology and Mutagenesis, Aging and Cancer Research, having authored 34 papers that have together received 2.8k indexed citations. Recurring topics across this work include Toxic Organic Pollutants Impact (8 papers), Cancer, Hypoxia, and Metabolism (5 papers), Muscle Physiology and Disorders (4 papers), Pharmacogenetics and Drug Metabolism (3 papers), Cholesterol and Lipid Metabolism (3 papers), Carcinogens and Genotoxicity Assessment (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Cancer, Lipids, and Metabolism (3 papers). The work is most often cited by research in Biological Psychiatry (431 citations), Behavioral Neuroscience (174 citations) and Hematology (376 citations). Colin A. Flaveny has collaborated with scholars based in United States, India and Switzerland. Frequent co-authors include Gary H. Perdew, Iain A. Murray, Brett C. DiNatale, Jennifer C. Schroeder, Elizabeth M. Laurenzana, Curtis J. Omiecinski, Albert E. Parker, Russell D. Romeo, John R. Walker and Michael P. Cooke. Their work appears in journals such as Science, PLoS ONE and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact